ClinicalTrials.gg
RecruitingNCT07260851Updated Dec 17, 2025

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions

A Phase 1 interventional study of DWJ1622 and DWC202313, DWC202314 in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fasting conditions.

Read the detailed description

This is an open-label, randomized, oral, single-dose, 2-sequence, 2-period, crossover Phase 1 study designed to compare the pharmacokinetics and safety profiles of DWJ1622 with the co-administration of DWC202313 and DWC202314 in healthy volunteers under fasting conditions. Subjects will be randomized to receive either DWJ1622 or the co-administration of DWC202313 and DWC202314 in different sequences across two study periods with an appropriate washout period.

The primary pharmacokinetic endpoints include the maximum observed plasma concentration (Cmax) and the area under the plasma concentration-time curve to the last measurable concentration (AUClast) of each study drug. Secondary endpoints include the area under the plasma concentration-time curve extrapolated to infinity (AUCinf), the ratio of AUClast to AUCinf (AUClast/AUCinf), the time to reach maximum plasma concentration (Tmax), and the terminal elimination half-life (t1/2). Safety will be evaluated based on adverse events and clinical laboratory tests.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 19 year old
  • Healthy adult volunteers

Exclusion criteria

Exclusion Criteria:

  • with a history of mental disorder
  • For female volunteers, those who are suspected of being pregnant or lactating
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    DWJ1622

    Drug: DWJ1622 · Drug: DWC202313, DWC202314

  • Experimental
    DWC202313, DWC202314

    Drug: DWJ1622 · Drug: DWC202313, DWC202314

Interventions

  • DrugDWJ1622

    DWJ1622 (single oral dose) is administered in accordance with the study protocol.

  • DrugDWC202313, DWC202314

    DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.

06

What researchers measure

Primary outcomes

  1. Cmax

    Cmax of DWJ1622 and DWC202313, DWC202314

    Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.

  2. AUClast

    AUClast of DWJ1622 and DWC202313, DWC202314

    Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.

Secondary outcomes

  1. AUCinf

    AUCinf of DWJ1622 and DWC202313, DWC202314

    Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.

  2. AUClast/AUCinf

    AUClast/AUCinf of DWJ1622 and DWC202313, DWC202314

    Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jan 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 3, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Jan 30, 2026
CompletionEst.
May 30, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07260851
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Nov 5, 2025
Primary completion
Jan 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Dec 17, 2025

Study contacts

SHIN
Contact
hbshin028@daewoong.co.kr
825508858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion